



# Molecular analysis of the human *SLC13A4* sulfate transporter gene promoter

J. Jefferis<sup>a</sup>, J. Rakoczy<sup>a,b,c</sup>, D.G. Simmons<sup>b</sup>, P.A. Dawson<sup>a,c,\*</sup>

<sup>a</sup> Mater Medical Research Institute, South Brisbane, Queensland, Australia

<sup>b</sup> School of Biomedical Sciences, University of Queensland, St. Lucia, Queensland, Australia

<sup>c</sup> Translational Research Institute, Woolloongabba, Queensland, Australia

## ARTICLE INFO

### Article history:

Received 10 February 2013

Available online 26 February 2013

### Keywords:

Sulfate  
Gene expression  
Placenta  
Transporter  
Transcription

## ABSTRACT

The human solute linked carrier (SLC) 13A4 gene is primarily expressed in the placenta where it is proposed to mediate the transport of nutrient sulfate from mother to fetus. The molecular mechanisms involved in the regulation of *SLC13A4* expression remain unknown. To investigate the regulation of *SLC13A4* gene expression, we analysed the transcriptional activity of the human *SLC13A4* 5'-flanking region in the JEG-3 placental cell line using luciferase reporter assays. Basal transcriptional activity was identified in the region –57 to –192 nucleotides upstream of the *SLC13A4* transcription initiation site. Mutational analysis of the minimal promoter region identified Nuclear factor Y (NFY), Specificity protein 1 (SP1) and Krüppel like factor 7 (KLF7) motifs which conferred positive transcriptional activity, as well as Zinc finger protein of the cerebellum 2 (ZIC2) and helix–loop–helix protein 1 (HEN1) motifs that repressed transcription. The conserved NFY, SP1, KLF7, ZIC2 and HEN1 motifs in the *SLC13A4* promoter of placental species but not in non-placental species, suggests a potential role for these putative transcriptional factor binding motifs in the physiological control of *SLC13A4* mRNA expression.

© 2013 Elsevier Inc. All rights reserved.

## 1. Introduction

Sulfate  $\text{SO}_4^{2-}$  is an essential nutrient for fetal growth and development [1]. The developing fetus has negligible capacity to generate its own sulfate and therefore is completely reliant on sulfate from the maternal circulation [2,3]. During pregnancy in humans and rodents, circulating maternal sulfate levels increase by  $\approx$ two-fold to meet the gestational requirements of the developing fetus [4–6]. Maternal hyposulfataemia has been linked to fetal sulfate deficiency and late gestational miscarriage in mice [6,7], demonstrating the importance for maintaining a sufficiently high sulfate supply to the developing fetus.

Supply of sulfate from maternal circulation to the fetus is mediated by sulfate transporter proteins that are expressed on the plasma membrane of placental trophoblast cells [1]. The mammalian genome contains ten sulfate transporter genes that have different tissue and cell membrane expression patterns [8]. Recent studies have shown abundant *SLC13A4* sulfate transporter mRNA expression in the syncytiotrophoblast cells (site of maternal–fetal nutrient exchange) of human and mouse placentae [9,10]. During mouse gestation, placental *SLC13A4* mRNA and protein levels increase by  $\geq$ four-fold in late gestation when fetal sulfate require-

ments are high [9]. These findings indicate that *SLC13A4* most likely plays an important role in mediating the placental transport of sulfate from mother to fetus.

Human, mouse and rat *SLC13A4* mRNA is most abundant in the placenta, with lower levels found in the choroid plexus [11–13], suggesting a physiological role for *SLC13A4* in both the placenta and brain. Lower levels of *SLC13A4* mRNA have been detected by PCR in other tissues, including testes and liver but the physiological contribution of *SLC13A4* to sulfate transport in those tissues is not known [11–13]. Nonetheless, abundant *SLC13A4* mRNA levels in the placentae of numerous species, indicates an important role of *SLC13A4* in mediating sulfate transport through the placenta. In addition, human *SLC13A4* amino acid sequence shares high identity ( $\geq$ 88%) with mouse and rat [11,12], indicating a possible conserved role of *SLC13A4* in mammalian physiology.

The human *SLC13A4* protein shares 40% amino acid identity with the human *SLC13A1* sulfate transporter, which is primarily expressed in the ileum and kidney where it maintains circulating sulfate levels [8]. Both *SLC13A1* and *SLC13A4* are localised to chromosome 7q31–33 [8], suggesting a gene duplication event through evolution. Numerous metabolic and physiological factors are known to regulate renal *SLC13A1* gene expression, including vitamin D and T3 responsive elements in the *SLC13A1* gene promoter [14,15]. Unlike the *SLC13A1* gene, there is currently no information regarding the molecular factors that regulate *SLC13A4* gene expression. The 5'-flanking regions of human, mouse and rat

\* Corresponding author. Address: Mater Research, Translational Research Institute, Woolloongabba, Queensland 4102, Australia.

E-mail address: [paul.dawson@mmri.mater.org.au](mailto:paul.dawson@mmri.mater.org.au) (P.A. Dawson).

*SLC13A4* contain numerous putative transcription factor binding motifs [11–13] but the role of these DNA sequences in regulating transcription have yet to be investigated.

In this study, we identified the minimal promoter sequence of the human *SLC13A4* 5'-flanking region that confers transcriptional activity. Phylogenetic alignment of the human minimal promoter sequence with multiple species, including both placental and non-placental animals, was performed to identify conserved putative transcription factor binding motifs. Finally, site-directed mutagenesis identified motifs that either up- or down-regulated transcriptional activity within the *SLC13A4* promoter. This is the first study to identify DNA sequences that potentially regulate the transcriptional activity of *SLC13A4* in numerous placental species.

## 2. Materials and methods

### 2.1. Bioinformatics

The NCBI database (<http://www.ncbi.nlm.nih.gov>) was queried for homologues of human *SLC13A4*. A phylogenetic tree of all species with *SLC13A4* homologues was generated online using the Interactive Tree of Life program (iTOL; <http://itol.embl.de/>) [16]. The 5'-flanking region of these genes from the predicted transcriptional start site to approximately –3500 bases upstream, were selected for sequence analysis as previously done for the related *SLC13A1* sulfate transporter gene [17]. Putative transcription factor binding motifs were identified using MatInspector [18] and then a multiple species alignment of those motifs was generated using the DiAlign TF program (<http://www.genomatix.de>). *In silico* methylation analysis of the human, rat and mouse *SLC13A4* 5'-flanking regions as well as *CYP24A1*, *Cyp24a1* and *SERPINB5* (control genes known to have methylated promoters) [19,20], was performed using CpG island searcher (<http://cpgislands.usc.edu/>) using recommended parameters for %GC content (55%), ratio of observed

to expected GC islands (0.65), 200 bp CpG island lengths and 100 bp distances between CpG islands [21].

### 2.2. Cell culture

The JEG-3 placental cell line was cultured in DMEM medium containing L-glutamine and glucose (Invitrogen) supplemented with 10% heat-inactivated fetal calf serum, 1% penicillin–streptomycin and 0.1% plasmocin (InvivoGen). Cultures were maintained at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air.

### 2.3. Promoter plasmid constructs

Fragments of the human *SLC13A4* 5'-flanking region, with a common 3'-end at +690 (+1 is the transcription start site) and 5'-ends of –3004, –1054, –488, –380, –192, –57 and –5 were amplified by PCR using 200 nM forward and reverse primers (Table 1) and 1.25 U LA TAQ polymerase (TakaRa). The thermal cycling protocol was: 95 °C for 1 min; 35 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 3 min, followed by 1 cycle of 72 °C for 10 min. Each fragment was cloned upstream of a luciferase reporter gene in the multiple cloning site of the pMetLuc2 expression vector (Clontech) using In-Fusion reagent as described by the manufacturer (Clontech). Sequence variants were introduced into the cloned –380 *SLC13A4* 5'-flanking region by PCR using 200 nM forward and reverse primers (Table 1) and thermal cycling parameters: 95 °C for 1 min; 25 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 3 min, followed by 1 cycle of 72 °C for 10 min. These PCR products were then treated with In-Fusion reagent (Clontech) to generate circularized vectors, as previously described [22]. Nucleotide sequences of all cloned *SLC13A4* sequences were verified by DNA sequence analysis using 1 µg plasmid DNA, 9.6 pmol forward and reverse primers (Table 1), ABI Prism BigDye

**Table 1**  
Primers used for PCR and DNA sequencing.

| Primer  | #Direction | Sequence (5'–3')                              | ##Primer location |
|---|------------|---|-------------------|
| *Primers used for PCR-amplifying <i>SLC13A4</i> 5'-flanking regions |            |   |                   |
| P1  | F          | <u>CATGGTGGCGACCGGT</u> CGCGCTCTGCTCTCCAG     | +690              |
| P2  | R          | <u>CCCGGGATCCACCGGT</u> TCCACTCCCTTGACAATGG   | –3004             |
| P3  | R          | <u>CCCGGGATCCACCGGT</u> TTAGCCTGGGGATCATTTCC  | –1054             |
| P4  | R          | <u>CCCGGGATCCACCGGT</u> CGATCTTTCAGCAGGGAG    | –488              |
| P5  | R          | <u>CCCGGGATCCACCGGT</u> CCAAGTCTAGATCAGCAGG   | –380              |
| P6  | R          | <u>CCCGGGATCCACCGGT</u> CCGCTGTGACCAATCAAGAG  | –192              |
| P7  | F          | <u>CCCGGGATCCACCGGT</u> GGCCTCCAGCAAGTTTGTC   | –57               |
| P8  | R          | <u>CCCGGGATCCACCGGT</u> CTTTCTGCTTTGACGCCACG  | –5                |
| **Primers used for site directed mutagenesis                        |            |   |                   |
| P9  | F          | CCATTGGTGGATGAAAC <u>CT</u> TAAAGGTGGGCCTCCAG | –67               |
| P10   | R          | TTCATCCACCAATGGGAAGCCGGGACAGAGACAG            |                   |
| P11   | F          | GATTGGCTTTGAGAAGT <u>TC</u> CGGAGCTACTGTCTC   | –113              |
| P12   | R          | TTCTCAAAGCCAATCAGCAAATGAAAAGAATGAG            |                   |
| P13   | F          | TCTTTTCAATTGCTG <u>TT</u> TGGCTTTGAGAAGTGGG   | –129              |
| P14   | R          | AGCAAATTGAAAAGAATGAGTCAATTTCTCTCCCC           |                   |
| P15   | F          | GCGGGAGAGAAATTGAC <u>CT</u> ATTCTTTCAATTG     | –149              |
| P16   | R          | AATTTCTCTCCCGCGCGCTCTTGATTGGTCAC              |                   |
| P19   | F          | GGAATCAGCAGGCCCGG <u>TT</u> TGACCAATCAAGAG    | –189              |
| P20   | R          | GGGCTGCTGATTCCGACAGACCTAGGCAGCCTG             |                   |
| ***Primers used for DNA sequencing                                  |            |   |                   |
| P21   | F          | CTGTGGATAACCGTATTAC                           |                   |
| P22   | R          | CAGATGTCGATGTTGGGG                            |                   |

\*F, forward primer; R, reverse primer. ##Number denotes the position of the first 5'-nucleotide in the 5'-flanking region of *SLC13A4*. \*Underlined sequence homologous to the pMetLuc2 vector to allow recombination cloning. \*\*Underlined nucleotides are mutated in the core sequences of HNF1-MYT1, SP1-KLF7, NFY, AP1 and ZIC2-HEN1 sites. \*\*\*Primers located in the pMetLuc2 vector.

Terminator Sequence chemistry and an AB3730x/96-capillary sequencer (Applied Biosystems).

#### 2.4. Transient transfections and luciferase assay

JEG-3 cells were transiently co-transfected using Lipofectamine<sub>2000</sub> (Invitrogen) with pMetLuc2 containing individual cloned *SLC13A4* fragments or pMetLuc2 that lacks cloned fragments (negative control), and pSEAP2 alkaline phosphatase expression vector used to normalise luciferase activity. Cells (80% confluent in 48 well plates) were incubated with 2  $\mu$ l Lipofectamine<sub>2000</sub> and plasmids (0.4  $\mu$ g each pMetLuc2 and pSEAP2) in DMEM containing 10% fetal calf serum (total volume 50  $\mu$ l) for 7 h, and then the media was replaced with 600  $\mu$ l OptiMEM<sup>®</sup> (Invitrogen) containing 10% fetal calf serum for an additional 70 h. Luciferase and alkaline phosphatase activities in the cell culture media were assayed using protocols and reagents (Ready-To-Glow<sup>™</sup> Dual secreted reporter assay) purchased from Clontech, and measured using a PolarStar Omega plate reader (BMG Labtech).

#### 2.5. Statistical analysis


The statistical significance of the differences of luciferase activities between each clone and control vector was evaluated using a one-way ANOVA, followed by a Dunnett multiple comparisons test, with  $P < 0.05$  considered significant.

### 3. Results and discussion

#### 3.1. Analysis of *SLC13A4* protein sequences and 5'-flanking regions of multiple species

From the NCBI database, we retrieved the *SLC13A4* gene sequences of 20 species, including human. Alignment of human *SLC13A4* amino acid sequences with the 19 homologues showed the highest homology (88%–99% identity) to hemochorial species, intermediate homology (64%–93% identity) with endotheliochorial and epitheliochorial species, and lowest homology (49%–79% identity) with non-placental species (Fig. 1A). These findings show that the human *SLC13A4* protein sequence is more highly conserved with most other placental species, particularly hemochorial species, when compared to non-placental species. In addition, the relatively high similarity (88% identity) between mouse and human *SLC13A4* amino acid sequences [11], together with recent data showing both human and mouse *SLC13A4* mRNA expression in placental syncytiotrophoblasts [9,10], indicates that mouse *SLC13A4* is likely to be a suitable model for studying the physiological roles of *SLC13A4* in the human placenta.

Within the first 3500 nucleotides upstream of the predicted transcription initiation start site of all 20 species analysed in this study, we identified 9 putative transcriptional binding motifs that were conserved in most of the placental species (Fig. 1B). These conserved motifs in the human *SLC13A4* 5'-flanking region are: High mobility group A (HMGA, 5'-TTGTGCAATCAATGACTGAAAA-3') at position –2805 to –2783; Homeobox D10 (HOXD10, 5'-TTTTTTTTTATTGTGGA-3') at position –1841 to –1825; overlapping Zinc finger protein of the cerebellum 2 (ZIC2, 5'-GCCCCGCTGTGACC-3') at position –196 to –182 and Helix-loop-helix transcription factor (HEN1, 5'-CAGGCCCGCTGTGACCAAT-3') at position –199 to –179; Nuclear factor Y (NFY, 5'-TTGCTGATTGGCTT-3') at position –135 to –121; overlapping Specificity protein 1 (SP1, 5'-GAAGTGGCGGAGCTAC-3') at position –118 to –102 and Krüppel like factor 7 (KLF7, 5'-AGAAGTGGCGGAGCTA-3') at position –119 to –103; and overlapping Hepatic nuclear



**Fig. 1.** Phylogenetic analysis of *SLC13A4* protein and the *SLC13A4* 5'-flanking region. (A) Phylogenetic tree of vertebrates that carry *SLC13A4*. Distances represent evolutionary divergence of species. Colors represent the placental types; hemochorial (red), endotheliochorial (purple), epitheliochorial (green); and non-placental species (blue). Image adapted from tree generated online using the Interactive Tree of Life (ITOL) [16]. (B) Multiple species alignment of conserved putative transcription factors in the *SLC13A4* 5'-flanking regions. Thirteen placental species shared six highly conserved domains with human *SLC13A4*: HMGA, HOXD10, ZIC2/HEN1, NFY, SP1/KLF7 and HNF1/MYT1. Regions A and B represent segments of human *SLC13A4* 5'-flanking region that confer negative and positive transcriptional regulation (see Fig. 2A). \*The transcriptional start sites have been identified in human [13], mouse [11] and rat [12], as indicated by the arrow. The species are divided into placental subtypes; hemochorial, endotheliochorial, epitheliochorial and non-placental. #The marsupial species (opossum and platypus) have a transient placenta early in development, which is functionally distinct to that of the other placental mammals [33], and share few conserved putative motifs with other placental species. Of the 5 non-placental species, only the zebra finch shares conserved putative transcription factors with the placental mammals. Scale bar at top is relative to the +1 of the transcriptional start site in human *SLC13A4*. (For interpretation of the references to color in this Fig. legend, the reader is referred to the web version of this article.)

factor 1 (HNF1, 5'-GGATGAAAGTTAAAGGT-3') at position –75 to –59 and Myelin transcription factor 1 (MYT1, 5'-TGAAAGT-TAAAGG-3') at position –72 to –60. In addition, human *SLC13A4* contains a consensus sequence for Activating protein 1 (AP1, 5'-AATTGACTCATTC-3') at position –156 to –144, which is not conserved with other *SLC13A4* homologues but is found in a similar position in the 5'-flanking region of the related human *SLC13A1* orthologue [17]. Furthermore, all 20 *SLC13A4* homologues lack

any canonical TATA-box, suggesting that *SLC13A4* mRNA expression is likely regulated by multiple transcription factors.


To investigate the potential epigenetic regulation of *SLC13A4* mRNA expression, we performed a bioinformatic analysis of the 5'-flanking regions of human, rat and mouse *SLC13A4*, as well as human *CYP24A1*, mouse *Cyp24a1* and human *SERPINB5* (positive controls), previously shown to have promoters regulated by CpG methylation [19,20]. Methylation was predicted for *CYP24A1*, *Cyp24a1* and *SERPINB5*, but the absence of CpG islands in all three *SLC13A4* homologues (Table 2), suggests that *SLC13A4* mRNA expression is unlikely to be regulated by methylation.

3.2. Minimal promoter sequence of human *SLC13A4*

To localise the DNA sequences of *SLC13A4* which are important for basal promoter activity, a series of reporter constructs with 5'-flanking regions of *SLC13A4* were cloned upstream of the luciferase gene, transfected into JEG-3 cells and then assayed for luciferase activity (Fig. 2A). The highest luciferase expression was obtained with fragments with the common 3'-end +690 and upstream 5'-ends at -192, -380, -488 and -1054, when compared to constructs with 5'-ends at -3004, -57 and -5. This finding suggests the possible presence of upstream negative regulatory motifs between -1054 and -3004 (region A, Fig. 1B), as well as downstream positive regulatory elements between -192 and -57 (region B, Fig. 1B).

Within region A, binding motifs for HMGA and HOXD10 were conserved in most placental species. Previous studies have shown that HMGA and HOXD10 can act a transcriptional repressors [23,24], which is consistent with our data showing the lowest luciferase activity in fragments containing the HMGA and HOXD10 binding sequences (Fig. 2A). However, the evaluation of these 2 sites to *SLC13A4* transcription will require additional studies.

Region B contains ZIC2, HEN1, NFY, SP1, KLF7, HNF1 and MYT1 motifs conserved in most placental species (Fig. 1B). Both ZIC2 and HEN1 are primarily expressed in the central nervous system [25,26], suggesting a potential role for the putative ZIC2 and HEN1 motifs in regulating *SLC13A4* expression in the brain. NFY, SP1 and KLF7 transcriptional factors are expressed in the placenta where they play a role in regulating placental development [27,28]. SP1 is a ubiquitous transcription factor that acts in concert with other transcription factors, including NFY [29], and is expressed in mouse syncytiotrophoblasts at the time of syncytialisation, when *SLC13A4* mRNA levels are up-regulated [9]. In addition, KLF7 is expressed towards the fetal side of the placenta during the third trimester of pregnancy [30], which correlates with the spatial and temporal expression of *SLC13A4* mRNA in mouse and human gestation [9,10]. Whilst HNF1 and MYT1 transcription fac-



**Fig. 2.** Transcriptional activities of the *SLC13A4* 5'-flanking region. (A) Transcriptional activity of the 5'-truncated *SLC13A4* 5'-flanking region assessed by luciferase activity in JEG-3 cells. Data is shown as fold induction to luciferase activity of the pMetLuc2 reporter,  $n = 3$ . \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  when compared to constructs containing the -3004 fragment. (B) Transcriptional activity of the pMetLuc2-380 vector containing wildtype (filled symbols) and individually mutated motifs (unfilled symbols): ZIC2/HEN1, AP1, NFY, SP1-KLF7 and HNF1-MYT1. Data is shown as fold induction to luciferase activity of the pMetLuc2 reporter,  $n = 3$ .

tors have not been detected in the placenta [31,32], the conserved sequence and location of these putative transcription factor binding motifs in *SLC13A4* of numerous placental species will require further investigation.

3.3. Transcriptional activity of motifs in the 5'-flanking region of human *SLC13A4*

To evaluate the contribution of putative ZIC2, HEN1, NFY, SP1, KLF7, HNF1, MYT1 and AP1 binding motifs to *SLC13A4* mRNA expression, we mutated the core sequences of each motif in the pMetLuc2-380 vector and compared luciferase activities to the control sequence (Fig. 2B). Luciferase expression from the mutated AP1 and overlapping HNF1 and MYT1 sequences was similar to the wildtype sequence, suggesting that these sites are not responsible for the transcriptional activity of the pMetLuc2-380 vector. These findings are also consistent with HNF1 and MYT1 transcription factors not being detected in the placenta [31,32], as well as the AP1 motif in human *SLC13A4* not found in the *SLC13A4* 5'-flanking region of other species. Mutational analysis of the overlapping ZIC2 and HEN1 sites showed  $\approx 50\%$  increase in luciferase activity, when compared to wildtype sequence, indicating that the ZIC2 and/or HEN1 motifs may negatively regulate transcription of *SLC13A4* in placental cells. Mutations in the core sequences of NFY and overlapping SP1 and KLF7 sites, led to partial ( $\approx 70\%$ ) and complete loss of transcription, respectively, induced by the *SLC13A4* sequences in pMetLuc2-380. These findings suggest that NFY and the SP1 and/or KLF7 sites may play important roles in the transcriptional activity of the human *SLC13A4* promoter. This finding is supported by the expression of the NFY, SP1 and KLF7 transcription factors in placental trophoblasts [27,28], where *SLC13A4* is expressed [9,10].

This is the first study to identify sequence elements in the *SLC13A4* 5'-flanking region that mediate enhanced or decreased transcriptional activity, and therefore may contribute to regulating sulfate supply to the developing fetus.

**Table 2**  
Methylation analysis of the human, rat and mouse *SLC13A4* 5'-flanking regions.

| Gene 5'-flanking region | CpG islands | #Exp <sub>CpG</sub> /Obs <sub>CpG</sub> | Predicted methylation |
|-------------------------|-------------|---|-----------------------|
| Human <i>SLC13A4</i>    | 0           | 0.65                                    | No                    |
| Rat <i>Slc13a4</i>      | 0           | 0.65                                    | No                    |
| Mouse <i>Slc13a4</i>    | 0           | 0.65                                    | No                    |
| *Human <i>CYP24A1</i>   | 2           | 0.68                                    | Yes                   |
| *Mouse <i>Cyp24a1</i>   | 1           | 0.68                                    | Yes                   |
| **Human <i>SERPINB5</i> | 1           | 0.72                                    | Yes                   |

#The ratio of expected CpG to observed CpG (Exp<sub>CpG</sub>/Obs<sub>CpG</sub>) investigates whether the number of CpG repeats is more so than expected by chance, and a CpG island is defined when Exp<sub>CpG</sub>/Obs<sub>CpG</sub> > 0.65. To test the validity of the software analysis three positive controls, which have methylation patterns confirmed through bisulfite sequencing, were included. \**CYP24A1* (vitamin D 24-hydroxylase) is methylated in human and mouse placenta [20] and \*\*Human *SERPINB5* (encodes the Maspin protein) which is methylated in maternal blood [19].



## Acknowledgments

The authors thank K. Richard (University of Queensland) for supplying the JEG-3 cell line. This study was supported by the Mater Medical Research Institute and the Mater Foundation.

## References

- [1] P.A. Dawson, Sulfate in fetal development, *Semin. Cell Dev. Biol.* 22 (2011) 653–659.
- [2] G. Gaull, J.A. Sturman, N.C. Raiha, Development of mammalian sulfur metabolism: absence of cystathionase in human fetal tissues, *Pediatr. Res.* 6 (1972) 538–547.
- [3] C. Loriette, F. Chatagner, Cysteine oxidase and cysteine sulfinic acid decarboxylase in developing rat liver, *Experientia* 34 (1978) 981–982.
- [4] D.E. Cole, L.S. Baldwin, L.J. Stirk, Increased inorganic sulfate in mother and fetus at parturition: evidence for a fetal-to-maternal gradient, *Am. J. Obstet. Gynecol.* 148 (1984) 596–599.
- [5] D.E. Cole, L.S. Baldwin, L.J. Stirk, Increased serum sulfate in pregnancy: relationship to gestational age, *Clin. Chem.* 31 (1985) 866–867.
- [6] P.A. Dawson, P. Sim, D.G. Simmons, D. Markovich, Fetal loss and hyposulfatemia in pregnant NaS1 transporter null mice, *J. Reprod. Dev.* 57 (2011) 444–449.
- [7] P.A. Dawson, L. Beck, D. Markovich, Hyposulfatemia, growth retardation, reduced fertility and seizures in mice lacking a functional NaS1 gene, *Proc. Natl. Acad. Sci. USA* 100 (2003) 13704–13709.
- [8] P.A. Dawson, D. Markovich, Genetic polymorphisms of human sulfate transporters, *Curr. Pharmacogenomics* 5 (2007) 262–274.
- [9] P.A. Dawson, J. Rakoczy, D.G. Simmons, Placental, Renal, and ileal sulfate transporter gene expression in mouse gestation, *Biol. Reprod.* 87 (2012) 1–9.
- [10] D.G. Simmons, J. Rakoczy, J. Jefferis, R. Lourie, H.D. McIntyre, P.A. Dawson, Human placental sulfate transporter mRNA profiling identifies abundant SLC13A4 in syncytiotrophoblasts and SLC26A2 in cytotrophoblasts, *Placenta* 323 (2013), <http://dx.doi.org/10.1016/j.placenta.2013.01.017>.
- [11] P.A. Dawson, K.J. Pirlo, S.E. Steane, K. Kunzelmann, Y.J. Chien, D. Markovich, Molecular cloning and characterization of the mouse Na<sup>+</sup> sulfate cotransporter gene (*Slc13a4*): structure and expression, *Genes Genet. Syst.* 81 (2006) 265–272.
- [12] P.A. Dawson, K.J. Pirlo, S.E. Steane, K.A. Nguyen, K. Kunzelmann, Y.J. Chien, D. Markovich, The rat Na<sup>+</sup>-sulfate cotransporter rNaS2: functional characterization, tissue distribution, and gene (*slc13a4*) structure, *Pflugers Arch.* 450 (2005) 262–268.
- [13] D. Markovich, R.R. Regeer, K. Kunzelmann, P.A. Dawson, Functional characterization and genomic organization of the human Na<sup>+</sup>-sulfate cotransporter hNaS2 gene (*SLC13A4*), *Biochem. Biophys. Res. Commun.* 326 (2005) 729–734.
- [14] P.A. Dawson, D. Markovich, Regulation of the mouse NaS1 promoter by vitamin D and thyroid hormone, *Pflugers Arch.* 444 (2002) 353–359.
- [15] P.A. Dawson, D. Markovich, Transcriptional regulation of the sodium-sulfate cotransporter NaS(i)-1 gene, *Cell Biochem. Biophys.* 36 (2002) 175–182.
- [16] I. Letunic, P. Bork, Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation, *Bioinformatics* 23 (2007) 127–128.
- [17] A. Lee, D. Markovich, Characterization of the human renal Na<sup>+</sup>-sulphate cotransporter gene (NAS1) promoter, *Pflugers Arch.* 448 (2004) 490–499.
- [18] K. Quandt, K. Frech, H. Karas, E. Wingender, T. Werner, MatInd and MatInspector – new fast and versatile tools for detection of consensus matches in nucleotide sequence data, *Nucleic Acids Res.* 23 (1995) 4878–4884.
- [19] S.S. Chim, Y.K. Tong, R.W. Chiu, T.K. Lau, T.N. Leung, L.Y. Chan, C.B. Oudejans, C. Ding, Y.M. Lo, Detection of the placental epigenetic signature of the maspin gene in maternal plasma, *Proc. Natl. Acad. Sci. USA* 102 (2005) 14753–14758.
- [20] B. Novakovic, M. Sibson, H.K. Ng, U. Manuelpillai, V. Rakyan, T. Down, S. Beck, T. Fournier, D. Evain-Brion, E. Dimitriadis, J.M. Craig, R. Morley, R. Saffery, Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface, *J. Biol. Chem.* 284 (2009) 14838–14848.
- [21] D. Takai, P.A. Jones, Comprehensive analysis of CpG islands in human chromosomes 21 and 22, *Proc. Natl. Acad. Sci. USA* 99 (2002) 3740–3745.
- [22] B. Zhu, G. Cai, E.O. Hall, G.J. Freeman, In-fusion assembly: seamless engineering of multidomain fusion proteins, modular vectors, and mutations, *BioTechniques* 43 (2007) 354–359.
- [23] D.G. Negorev, O.V. Vladimirova, A. Ivanov, F. Rauscher 3rd, G.G. Maul, Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression, *J. Virol.* 80 (2006) 8019–8029.
- [24] X. Li, S. Nie, C. Chang, T. Qiu, X. Cao, Smads oppose Hox transcriptional activities, *Exp. Cell Res.* 312 (2006) 854–864.
- [25] Y. Yang, C.K. Hwang, E. Junn, G. Lee, M.M. Mouradian, ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene, *J. Biol. Chem.* 275 (2000) 38863–38869.
- [26] C. Manetopoulos, A. Hansson, J. Karlsson, J.I. Jönsson, H. Axelsson, The LIM-only protein LMO4 modulates the transcriptional activity of HEN1, *Biochem. Biophys. Res. Commun.* 307 (2003) 891–899.
- [27] J.N. Li, Y.C. Ge, Z. Yang, C.M. Guo, T. Duan, L. Myatt, H. Guan, K. Yang, K. Sun, The Sp1 transcription factor is crucial for the expression of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in human placental trophoblasts, *J. Clin. Endocrinol. Metab.* 96 (2011) E899–E907.
- [28] I. Krüger, M. Vollmer, D.G. Simmons, H.P. Elsässer, S. Philipsen, G. Suske, Sp1/Sp3 compound heterozygous mice are not viable: impaired erythropoiesis and severe placental defects, *Dev. Dyn.* 236 (2007) 2235–2244.
- [29] K. Yamada, H. Kanda, S. Tanaka, N. Takamatsu, T. Shiba, M. Ito, Sox15 enhances trophoblast giant cell differentiation induced by Hand1 in mouse placenta, *Differentiation* 74 (2006) 212–221.
- [30] L. Blanchon, J.L. Bocco, D. Gallot, A.M. Gachon, D. Lémy, P. Déchelotte, B. Dastugue, V. Sapin, Co-localization of KLF6 and KLF4 with pregnancy-specific glycoproteins during human placenta development, *Mech. Dev.* 105 (2001) 185–189.
- [31] S.A. Duncan, K. Manova, W.S. Chen, P. Hoodless, D.C. Weinstein, R.F. Bachvarova, J.E. Darnell Jr, Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst, *Proc. Natl. Acad. Sci. USA* 91 (1994) 7598–7602.
- [32] L.D. Hudson, E. Romm, J.A. Berndt, J.A. Nielsen, A tool for examining the role of the zinc finger myelin transcription factor 1 (Myt1) in neural development: Myt1 knock-in mice, *Transgenic Res.* 20 (2011) 951–961.
- [33] F. Zeller, Early ontogeny and placentation of the grey short-tailed opossum, *Monodelphis domestica* (Didelphidae: Marsupialia): contribution to the reconstruction of the marsupial morphotype, *J. Zool. Sys. Evol. Res.* 39 (2001) 137–158.